What if the future of HER2‐positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
What if the future of HER2‐positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study
Authors
Keywords
-
Journal
Cancer Medicine
Volume 11, Issue 2, Pages 332-339
Publisher
Wiley
Online
2021-12-18
DOI
10.1002/cam4.4449
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- LncRNA PSMB8-AS1 contributes to pancreatic cancer progression via modulating miR-382-3p/STAT1/PD-L1 axis
- (2020) Hao Zhang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Plasma microRNA levels for predicting therapeutic response to neoadjuvant treatment in HER2-positive breast cancer: Results from the NeoALTTO trial
- (2019) Serena Di Cosimo et al. CLINICAL CANCER RESEARCH
- The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study
- (2019) Serena Di Cosimo et al. EUROPEAN JOURNAL OF CANCER
- MiR-205 as predictive biomarker and adjuvant therapeutic tool in combination with trastuzumab
- (2018) Alessandra Cataldo et al. Oncotarget
- HER2-positive breast cancer is lost in translation: time for patient-centered research
- (2017) Isabelle Gingras et al. Nature Reviews Clinical Oncology
- Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
- (2017) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Developing miRNA signatures: a multivariate prospective
- (2016) Paolo Verderio et al. BRITISH JOURNAL OF CANCER
- MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients
- (2015) Leticia De Mattos-Arruda et al. Oncotarget
- MiR-200c suppresses TGF-β signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB1 in breast cancer
- (2014) Wen-Dong Bai et al. INTERNATIONAL JOURNAL OF CANCER
- Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response
- (2014) Evandro de Azambuja et al. LANCET ONCOLOGY
- Predicting Degree of Benefit From Adjuvant Trastuzumab in NSABP Trial B-31
- (2013) Katherine L. Pogue-Geile et al. JNCI-Journal of the National Cancer Institute
- Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
- (2012) José Baselga et al. LANCET
- Up-regulation ofmiR-21Mediates Resistance to Trastuzumab Therapy for Breast Cancer
- (2011) Chang Gong et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data
- (2011) Hajime Uno et al. STATISTICS IN MEDICINE
- A novel and universal method for microRNA RT-qPCR data normalization
- (2009) Pieter Mestdagh et al. GENOME BIOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started